Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup
DeviceTalks Weekly: Ep. 13 – Cala Health CEO Renee Ryan Brings Business Building Insights to Bioelectronic Medicine Startup
In this week’s episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health.
Ryan came to Cala from the venerable medtech investor Johnson & Johnson Development Corp., where she made over 15 investments helping to create companies including Auris Surgical, Cala and digital surgery play Verb Surgical, J&J’s joint venture with Verily. “I really set my mind to [asking] was there a way we could create our own opportunities,” she said of her eight years as the corporate investor.
We ask Ryan about her move into medtech investing from investment banking as well as the “secret power” that helped her succeed as an investor and an executive.
We’ll also discuss the unique commercial strategy Cala is employing as it begins rolling out its Cala Trio, a bioelectronic device developed to treat essential tremor.
The interview was conducted in February.
What role will tech companies play in medtech’s future?
Did Verb Surgical meet her expectations?
As CEO how do you manage investor syndicates with multiple corporate investors?
Can Cala secure reimbursement and create a new market for tremors?
What grade did she skip as a child?
Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
In this week’s episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health.
Ryan came to Cala from the venerable medtech investor Johnson & Johnson Development Corp., where she made over 15 investments helping to create companies including Auris Surgical, Cala and digital surgery play Verb Surgical, J&J’s joint venture with Verily. “I really set my mind to [asking] was there a way we could create our own opportunities,” she said of her eight years as the corporate investor.
We ask Ryan about her move into medtech investing from investment banking as well as the “secret power” that helped her succeed as an investor and an executive.
We’ll also discuss the unique commercial strategy Cala is employing as it begins rolling out its Cala Trio, a bioelectronic device developed to treat essential tremor.
The interview was conducted in February.
What role will tech companies play in medtech’s future?
Did Verb Surgical meet her expectations?
As CEO how do you manage investor syndicates with multiple corporate investors?
Can Cala secure reimbursement and create a new market for tremors?
What grade did she skip as a child?
Don’t miss an episode! Subscribe to DeviceTalks Weekly on your podcast players.
Activity